UK initiative offers up to £6 million for research leading to novel therapies for serious bacterial infections
Photo credits: zverge / BigStock
One of the UK’s largest initiatives for combating antimicrobial resistance, Pathways to Antimicrobial Clinical Efficacy (Pace), has announced up to £6 million in funding to drive new research, supporting the development of novel therapies for serious bacterial infections.
“This latest funding round [. . .] reflects our commitment to support the most innovative global research in AMR, and we’re excited that we can now support even more pioneering projects that have the potential to save lives and protect future generations from drug-resistant infections,” said Beverley Isherwood, programme director of Pace.
This is the third Pace funding round to support innovative therapeutic projects, aiming to accelerate early-stage drug and diagnostic development targeting resistant bacterial infections with the highest global health burden. The call is designed to fill a critical gap in the…
Discover the latest in research funding every Tuesday with Funding Newswire. Dive into detailed articles with our monthly or yearly subscriptions or start with a free trial
NOTE: if you're a part of one of our Network member organisations, you get free access by signing up with your institutional email. Verify your eligibility here.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.